An update from Tempus AI, Inc. Class A ( (TEM) ) is now available.
On May 6, 2025, Tempus AI, Inc. reported its financial results for the first quarter of 2025, showcasing a 75.4% increase in revenue year-over-year to $255.7 million and a 99.8% rise in gross profit. The company announced strategic collaborations with AstraZeneca and Pathos to develop a multimodal foundation model in oncology, projected to bring in $200 million over the next three years. Tempus also completed the acquisition of Ambry Genetics and disclosed a collaboration with Illumina to enhance genomic algorithms. Despite reporting a net loss of $68 million, Tempus improved its adjusted EBITDA significantly compared to the previous year and increased its full-year revenue guidance to $1.25 billion, representing an 80% growth year-over-year.
Spark’s Take on TEM Stock
According to Spark, TipRanks’ AI Analyst, TEM is a Neutral.
Tempus AI, Inc. shows strong revenue growth and positive strategic developments, yet faces substantial financial challenges, including high leverage and negative cash flows. The earnings call provides an optimistic outlook with strategic initiatives and partnerships expected to drive future growth. However, the company’s valuation and technical indicators suggest caution, as persistent losses and mixed market momentum create uncertainty. Overall, the stock is positioned in a recovery phase but requires careful monitoring of financial stability and execution of strategic plans.
To see Spark’s full report on TEM stock, click here.
More about Tempus AI, Inc. Class A
Tempus AI, Inc. is a technology company that leverages artificial intelligence to advance precision medicine and patient care. It operates one of the world’s largest libraries of multimodal data and provides AI-enabled precision medicine solutions to physicians, aiming to deliver personalized patient care and facilitate the discovery, development, and delivery of optimal therapeutics.
Average Trading Volume: 12,806,644
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.87B
For a thorough assessment of TEM stock, go to TipRanks’ Stock Analysis page.